Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 38, Issue 30, Pages 3468-+Publisher
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.20.01924
Keywords
-
Categories
Funding
- Janssen-Cilag (Inst)
- GlaxoSmithKline (Inst)
- Eli Lilly (Inst)
- AstraZeneca (Inst)
- AstraZeneca
- Roche
- Merck (Inst)
- Boston Biomedical (Inst)
- Acetylon (Inst)
- Bristol Myers Squibb
- Agenus
- CytomX Therapeutics
- Tesaro (Inst)
- Clovis Oncology
- Vigeo Therapeutics (Inst)
- Arch Oncology (Inst)
- PTC Therapeutics
- Genentech (Inst)
- Lilly Foundation (Inst)
- Advaxis
- Verastem
- Novartis Pharmaceuticals UK
- Agenus (Inst)
- Takeda
- Stem CentRx (Inst)
- Immunogen
- Bayer
- Novogen
- Stemcentrx
- Celgene
- Tesaro
- Kite Pharma
- GOG Foundation (Inst)
- Atara Biotherapeutics (Inst)
Ask authors/readers for more resources
PURPOSETo provide recommendations on the use of poly(ADP-ribose) polymerase inhibitors (PARPis) for management of epithelial ovarian, tubal, or primary peritoneal cancer (EOC).METHODSRandomized, controlled, and open-labeled trials published from 2011 through 2020 were identified in a literature search. Guideline recommendations were based on the review of the evidence, US Food and Drug Administration approvals, and consensus when evidence was lacking.RESULTSThe systematic review identified 17 eligible trials.RECOMMENDATIONSThe guideline pertains to patients who are PARPi naive. All patients with newly diagnosed, stage III-IV EOC whose disease is in complete or partial response to first-line, platinum-based chemotherapy with high-grade serous or endometrioid EOC should be offered PARPi maintenance therapy with niraparib. For patients with germline or somatic pathogenic or likely pathogenic variants in BRCA1 (g/sBRCA1) or BRCA2 (g/sBRCA2) genes should be treated with olaparib. The addition of olaparib to bevacizumab may be offered to patients with stage III-IV EOC with g/sBRCA1/2 and/or genomic instability and a partial or complete response to chemotherapy plus bevacizumab combination. Maintenance therapy (second line or more) with single-agent PARPi may be offered for patients with EOC who have not received a PARPi and have responded to platinum-based therapy regardless of BRCA mutation status. Treatment with a PARPi should be offered to patients with recurrent EOC that has not recurred within 6 months of platinum-based therapy, who have not received a PARPi and have a g/sBRCA1/2, or whose tumor demonstrates genomic instability. PARPis are not recommended for use in combination with chemotherapy, other targeted agents, or immune-oncology agents in the recurrent setting outside the context of a clinical trial. Recommendations for managing specific adverse events are presented. Data to support reuse of PARPis in any setting are needed.Additional information is available at www.asco.org/gynecologic-cancer-guidelines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available